Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 26

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 26
---
 attendance at the extraordinary shareholders’ meeting. Yours sincerely,

| On behalf of the Board of Directors of NLS Pharmaceutics Ltd. |
| /s/ Ronald Hafner                                             |
| Ronald Hafner                                                 |
| Chairman of the Board of Directors                            |

Appendices: Appendix 1: Invitation
Appendix 2: Registration Form
Appendix 3: Proxy Card THE BOARD OF DIRECTORS HAS DETERMINED AND BELIEVES THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS ADVISABLE TO, AND IN THE BEST INTERESTS OF, NLS AND ITS SHAREHOLDERS AND HAS APPROVED EACH SUCH PROPOSAL. THE BOARD OF DIRECTORS RECOMMENDS THAT NLS SHAREHOLDERS VOTE “FOR” EACH SUCH PROPOSAL.

Appendix 1 Invitation To the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich, September5, 2025 Postponement to the Extraordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The board of directors of NLS Pharmaceutics Ltd. (the “ Board of Directors”), with registered office at The Circle6, 8058 Zurich, Switzerland (the “ Company”), is pleased to invite you to the extraordinary shareholders’ meeting of the Company (the “ NLS Meeting”). The shareholders’ meeting will be held as follows:

| – Date:         |     | September 29, 2025                                                                             |
|:----------------|:----|:-----------------------------------------------------------------------------------------------|
| – Doors open:   |     | 15:45 (CEST)                                                                                   |
| – Meeting time: |     | 16:00 (CEST)                                                                                   |
| – Place:        |     | At the premises of Baker McKenzie Switzerland AG, Holbeinstrasse 30, 8034 Zurich, Switzerland. |

The agenda items to be voted on, the voting instructions and the appendices mentioned herein are provided below: The Board of Directors reserves the right, for important reasons in the interest of the Company, to withdraw all subsequent proposals should any agenda item be rejected by the shareholders. In this case, none of the agenda items would be put to a vote. The agenda items and proposals of the Board of Directors are as follows: 1.Advisory vote: Approval of Merger Agreement Explanation:The Company entered into a merger agreement with Kadimastem Ltd. (“ Kadimastem”) on November 4, 2024 (“ Mer